[1]UdayakumarP.BalasubramanianSRamalingamKS.elat.cutaneous maniftestations inpatients with chronic renal failure on hemodiaysis[J].Indian Dermatol Venereol Leprol, 2006, 72(2):119-125
[2]王世相，李寒，何焱玲等.维持性血液透析终末期肾病患者皮肤病变调查分析[J].中华肾皮肤病杂志, 2008, 1(41):32-35
[3] Saray Y, Se?kin D, Bilezik?i B.Acquired perforating dermatosis: clinicopathological features in twenty-two cases [J].Eur Acad Dermatol Venereol, 2006, 20(6):79-88
[4]Hari KumarKV, PrajapatiJ, PavanG, et al.Acquired perforating dermatoses in patients with diabetic kidney disease on hemodialysis[J].Hemodial Int, 2010, 14(1):73-77
[5] Knable AL Jr . 2002; 7(20):513-521, [J].Dermatol Clin, 2002, 7(20):513-521
[6]FeiC, WangY, GongY, et al.Acquired reactive perforating collagenosis: a report of a typical case[J].Medicine(Baltimore), 2016, 95(30):1-4
[7]Dantas A, Melo G.Um caso de dermatose perfurante adquirida[J].Rev Port Clin Geral., 2011, 27(3):78-80
[8]Tamihiro KawakamI el at.Clinical practice guide for the treatment of perforating dermatosis[J].Journal of Dermatology, 2020, 47:1374-1382
[9]Wagner G, Sachse MM.Acquired reactive perforating dermatosis [J].Dtsch Dermatol Ges, 2013, 11:723-730
[10]Tilz H, Becker JC, Legat F, el at.Allopurinol in the treatment of acquired reactive perforating collagenosis[J].An Bras Dermatol, 2013, 88:94-97
[11]Grobner T.Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [J].Nephrol Dial Transplant, 2006, 21(4):1104-1108
[12]Girardi M, Kay J, Elston DM, elat, Cowper SE.Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. [J].Am Acad Dermatol, 2011, 65:1095-1097
[13]Prince MR, Zhang H, Morris M, et al.Incidence of nephrogenic systemic fibrosis at two large medical centers[J].Radiology, 2008, 248(3):807-816
[14] Gibson SE, Farver CF, Prayson RA.Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature [J].Arch Pathol Lab Med, 2006, 130(2):209-212
[15] Cowper SE.Nephrogenic fibrosing dermopathy: the first 6 years[J].Curr Opin Rheumatol,, 2003, 15(6):785-790
[16] Swaminathan S, Shah SV.New insights into nephrogenic systemic fibrosis[J].Am Soc Nephrol, 2007, 18(10):2636-2643
[17] Haemel AK, Sadowski EA, Shafer MM, el at.Update on nephrogenic systemic fibrosis: are we making progress?[J].Int J Dermatol, 2011, 50(6):659-666
[18]Knopp EA, Cowper SE.Nephrogenic systemic fibrosis: early recognition and treatment[J].Semin Dial., 2008, 21:123-128
[19] Elmholdt TR, Buus NH, Ramsing M, elat.Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial[J].Eur Acad Dermatol Venereol, 2013, 27:779-784
[20] Tran KT, Prather HB, Cockerell CJ, elat.UV-A1 therapy for nephrogenic systemic fibrosis[J].Arch Dermatol, 2009, 14:1170-1174
[21] Poisson JL, Low A, Park YA.The treatment of nephrogenic systemic fibrosis with therapeutic plasma exchange [J].Clin Apher, 2013, 28:317-320
[22] Leung N, Shaikh A, Cosio FG, et al.The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation[J].Am J Transplant, 2010, 10:558-562
[23] Sassa S.Modern diagnosis and management of the porphyrias[J].Br J Haematol, 2006, 135(6):281-292
[24] Farrag MS, Mikula I, Richard E, Saudek V, De Verneuil H, Martásek P.Hepatoerythropoietic Porphyria Caused by a Novel Homoallelic Mutation in Uroporphyrinogen Decarboxylase Gene in Egyptian Patients[J].Folia Biol (Praha), 2015, 61(6):219-226
[25] Cordova KB, Oberg TJ, Malik M, Robinson-Bostom L.Dermatologic conditions seen in end-stage renal disease[J].Semin Dial, 2009, 22(1):45-55
[26] Frank J, Poblete-Gutierrez P. Porphyria cutanea tarda – when skin meets liver[J].Best Pract Res Clin Gastroenterol, 2010, 24(5):735-745
[27] Markova A, Lester J, Wang J, Robinson-Bostom L.Diagnosis of common dermopathies in dialysis patients: a review and update[J].Semin Dial, 2012, 25:408-418
[28] Ryali ME, Whittier WL.Bullous skin lesions in a patient undergoing chronic hemodialysis[J].Semin Dial, 2010, 23(1):83-87
[29] Shieh S, Cohen JL, Lim HW.Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review[J]. Am Acad Dermatol, 2000, 42:645-652
[30]Alina Markova，el at.Diagnosis of Common Dermopathies in Dialysis Patients: A Review and Update[J].Seminars in Dialysis, 2012, 25(4):408-418
[31]Cooke NS, McKenna K. A case of haemodialysis-associated pseudoporphyria successfully treated with oral N-acetylcysteine[J].Clin Exp Dermatol, 2007, 32(1):64-66
[32] Berghoff AT, English JC III.Imatinib mesylate-induced pseudoporphyria[J].Am Acad Dermatol , 2010, 63(1):e14-e16
[33]Nigwekar SU，Zhao S，Wenger J，et al.A Nationally Representative Study of Calcificuremic Arteriolopathy Risk Factors [J].Amsoc Nephrol, 2016, 11:3421-3429
[34]何小苗.何正全; 维持性血液透析患者皮肤钙化1例[J].Chinese Journal ofRural Medicine and Pharmacy., 2015, (13):44-44
[35] Nigwekar SU, Bhan I, Turchin A, et al.Statin use and calcific uremic arteriolopathy: a matched case-control study[J].Am J Nephrol, 2013, 37:325-332
[36] Scott G.Westphal; Troy Plumb. Calciphylaxis. [J].StatPearls Publishing, 2021, :-
[37] Nigwekar SU, Thadhani R, Brandenburg VM.Calciphylaxis[J].N Engl J Med, 2018, 378(18):1704-1714
[38]Bazari H，Jaffect MR, Mannstadt M，et al.Case records of the Massachusetts General Hospital.Case 7-2007.A 59 -year-old woman with diabetic renal disease and nonhealing skin ulcers[J].N Engl J Med, 2007, 356(10):1049-1057
[39] Robinson-Bostom L, DiGiovanna JJ.Cutaneous manifestations of end-stage renal disease[J].JAm Acad Dermatol, 2000, 43:975-986
[40]Kangs JW，Madhan K，. Gastrointestinal Manifestations in a Patient With Calciphylaxis ：A case Report[J].Case RepN ephrol Dial, 2000, 43:975-986
[41] Nigwekar SU.Calciphylaxis [J].Curr Opin Nephrol Hypertens, 2017, 26:276-281
[42] Sagar U el at..Calciphylaxis: Risk Factors, Diagnosis, and Treatment 2015 July; 66(1): 133–146.[J].Am J Kidney Dis, 2015, 66(1):133-146
[43] Skalnik J, Vasku J, Urbanek E.Calciphylaxis and cerebral atrophy in man[J].Clinical orthopaedics and related research, 1970, 69:172-180
[44] Nigwekar SU, Kroshinsky D, Nazarian RM, et al.Calciphylaxis: risk factors, diagnosis, and treatment[J].Am J Kidney Dis, 2015, 66:133-146
[45] Bourgeois P, De Haes P.Sodium thiosulfate as a treatment for calciphylaxis: a case series[J].Dermatolog Treat, 2016, 27:520-524
[46] Polizzotto MN, Bryan T, Ashby MA, Martin P.Symptomatic management of calciphylaxis: a case series and review of the literature [J].Pain Symptom Manag, 2006, 32(2):186-190
[47]Erfurt-Berge C, Renner R.Management of patients with calciphylaxis: current perspectives[J].Chronic Wound Care Manag Res, 2019, 6:109-115
[48] Perkovic V, Neal B.Trials in kidney disease—time to EVOLVE[J].N Engl J Med, 2012, 367(26):2541-2542
